Efficacy of caffeine in adcy5-related dyskinesia: A retrospective study
Publication Details
Meneret, A.,
Mohammad, S.,
Cif, L.,
Doummar, D.,
DeGusmao, C.,
Anheim, M.,
Barth, M.,
Damier, P.,
Demonceau, N.,
Roze, E.,
Gallea, C.,
Gras, D.,
Gurgel-Giannetti, J.,
Innes, E.,
Necpal, J.,
Riant, F.,
Sandrine, S.,
Sarret, C.,
Seliverstov, Y.,
Paramanandam, V.,
Shetty, K.,
Tranchant, C.,
Doulazmi, M.,
Vidailhet, M.,
Pringsheim, T.,
&
Friedman, J.
(2022).
Efficacy of caffeine in adcy5-related dyskinesia: A retrospective study.
Movement Disorders, 37 (6), 1294-1298.
Abstract
Background: ADCY5-related dyskinesia is characterized by early-onset movement dis-orders. There is currently no validated treatment, but anecdotal clinical reports and biological hypotheses suggest efficacy of caffeine.
Objective: The aim is to obtain further insight into the efficacy and safety of caffeine in patients withADCY5-related dyskinesia
Results: Caffeine was overall well tolerated, even in children, and 87% of patients reported a clear improvement. Caffeine reduced the frequency and duration of paroxysmal movement disorders but also improved. baseline movement disorders and some other motor and nonmotor features, with consistent quality-of-life improvement. Three patients reported worsening.
Methods: A retrospective study was conducted worldwide in 30 patients with a provenADCY5muta-tion who had tried or were taking caffeine for dyskinesia. Disease characteristics and treatment responses were assessed through a questionnaire
Conclusion: Our findings suggest that caffeine should be considered as a first-line therapeutic option inADCY5-related dyskinesia. © 2022 International Parkinson and Movement Disorder Society
Keywords
ADCY5, paroxysmal dyskinesia, caffeine, dystonia, hyperkinetic
Link to Publisher Version (URL)
